Physician profile
Ilora Rafique
NPI 1992822043
$7,399.13
in general payments reported to CMS, 2019-2025
15 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $647 · 2021: $1,087 · 2022: $727 · 2023: $402 · 2024: $441 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,255.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Intra-Sana Laboratories | $599.64 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lilly USA, LLC | $517.43 | 2021-2025 | Kisunla |
| Gilead Sciences, INC. | $283.01 | 2020-2025 | |
| Abbott Laboratories | $264.59 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.79 | 2025 | Caplyta |
| Abbvie INC. | $249.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.14 | 2025 | Jardiance |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Allergan, INC. | $125.00 | 2020 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $122.31 | 2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.94 | 2023 | Trulance |
| Tactile Systems Technology INC | $67.91 | 2019 | |
| Horizon Therapeutics Plc | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilora Rafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.